Quantcast

Latest Amides Stories

2014-04-23 20:23:23

WHIPPANY, N.J. and THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., April 23, 2014 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced that The Lancet published online results from the Phase 3 DECISION trial which demonstrated that NEXAVAR(®) (sorafenib) tablets significantly extended the time patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is...

2014-04-23 09:37:13

In patients with idiopathic intracranial hypertension and mild vision loss, the use of the drug acetazolamide, along with a low-sodium weight-reduction diet, resulted in modest improvement in vision, compared with diet alone, according to a study in the April 23/30 issue of JAMA, a neurology theme issue. Idiopathic intracranial hypertension (IIH) is a disorder primarily of overweight women of childbearing age, characterized by increased intracranial pressure with its associated signs and...

2014-04-19 23:02:45

http://www.DrugNews.net is the web’s premier source for prescription drug warnings, research, side effects and legal news. Visit the DrugNews Center today. Chicago, IL (PRWEB) April 19, 2014 The prescription drug safety advocates at DrugNews.net are alerting patients taking the blood thinner Pradaxa of new information on the site. As the number of lawsuits alleging the drug caused internal bleeding continue to rise, its use has been expanded to include treatment of deep vein thrombosis...

2014-04-17 23:01:33

The Firm is actively evaluating Byetta lawsuit claims on behalf of diabetics who allegedly developed pancreatitis, pancreatic cancer or thyroid cancer after taking the incretin mimetic. New York, NY (PRWEB) April 17, 2014 More than 30 federal cases have joined a federal diabetes drug litigation that includes an increasing number of Byetta lawsuit (http://www.byettalawsuit.com/) filings, as well as claims over similarly-designed medications, Bernstein Liebhard LLP reports. Court documents...

2014-04-15 23:10:44

A new study published in The Oncologist journal shows that a subset of patients with advanced differentiated thyroid cancer (DTC) and multiple comorbidities in which full-dose sorafenib is considered unsafe can initiate treatment with sorafenib at lower starting doses without adversely affecting efficacy or tolerability compared with full-dose sorafenib. A team of researchers led by Ramona Dadu, MD, at the MD Anderson Cancer Center in Houston, TX, performed a retrospective analysis to...

2014-04-09 23:01:49

Pradaxa Lawsuits Now Pending in Federal Multidistrict Litigation Continue as Conference is Scheduled Columbus, OH (PRWEB) April 09, 2014 Wright & Schulte LLC, an experienced personal injury law firm representing plaintiffs in Pradaxa lawsuits, reports that a Status Conference has been scheduled for April 9, 2014 at 10:30 CT in the federal multidistrict ligation underway in Illinois for Pradaxa bleeding claims. According to court documents, at least 2,488 Pradaxa lawsuits have been...

2014-04-08 23:32:12

http://www.DrugNews.net is the web’s premier source for prescription drug warnings, research, side effects and legal news. Visit the DrugNews Center today. Chicago, IL (PRWEB) April 08, 2014 The prescription drug safety advocates at DrugNews.net are alerting patients taking the blood thinner Pradaxa of new information on the site. As the number of lawsuits alleging the drug caused internal bleeding continue to rise, researchers have reported a possible antidote*. DrugNews is a free...

2014-04-08 12:31:49

Three pivotal trials showed PRADAXA as non-inferior to warfarin in reduction of DVT and PE recurrence; fourth pivotal trial showed PRADAXA reduced risk of recurrence by 92 percent compared to placebo RIDGEFIELD, Conn., April 8, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa(®) (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in...

2014-04-07 08:31:34

Three pivotal trials showed PRADAXA as non-inferior to warfarin in reduction of DVT and PE recurrence; fourth pivotal trial showed PRADAXA reduced risk of recurrence by 92 percent compared to placebo RIDGEFIELD, Conn., April 7, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa(®) (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in...

2014-04-02 23:33:40

Boehringer Ingelheim ordered to pay nearly $1 million fine for obstructing pre-trial evidence gathering. National network of attorneys continues policy of no-cost consultations to consumers inquiring about legal options to seek compensation over these allegations. San Diego, CA (PRWEB) April 02, 2014 http://www.resource4thepeople.com/defectivedrugs/pradaxa-lawsuits.html Resource4thePeople today announced important new developments involving lawsuits* alleging that the popular...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related